S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Former Deutsche Bank Co-CEO Anshu Jain dies
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Germany urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Former Deutsche Bank Co-CEO Anshu Jain dies
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Germany urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Former Deutsche Bank Co-CEO Anshu Jain dies
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Germany urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Former Deutsche Bank Co-CEO Anshu Jain dies
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Germany urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
NYSE:BDX

Becton, Dickinson and - BDX Stock Forecast, Price & News

$263.69
+4.29 (+1.65%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$259.86
$263.97
50-Day Range
$234.16
$263.69
52-Week Range
$231.46
$280.62
Volume
830,905 shs
Average Volume
889,830 shs
Market Capitalization
$75.20 billion
P/E Ratio
45.46
Dividend Yield
1.32%
Price Target
$271.71

Becton, Dickinson and MarketRank™ Forecast

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
3.0% Upside
$271.71 Price Target
Short Interest
Healthy
0.99% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.17
Upright™ Environmental Score
News Sentiment
-0.04mentions of Becton, Dickinson and in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$2.51 M Sold Last Quarter
Proj. Earnings Growth
7.60%
From $11.31 to $12.17 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

165th out of 1,135 stocks

Surgical & Medical Instruments Industry

12th out of 114 stocks

BDX stock logo

About Becton, Dickinson and (NYSE:BDX) Stock

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Analysts Set New Price Targets

BDX has been the topic of several research analyst reports. Piper Sandler reduced their target price on Becton, Dickinson and from $265.00 to $255.00 in a research note on Thursday, May 5th. Morgan Stanley dropped their price target on Becton, Dickinson and from $282.00 to $272.00 and set an "overweight" rating on the stock in a research report on Friday, July 15th. StockNews.com upgraded Becton, Dickinson and from a "hold" rating to a "buy" rating in a research report on Wednesday, August 3rd. Citigroup lowered Becton, Dickinson and from a "neutral" rating to a "sell" rating and dropped their price target for the company from $265.00 to $235.00 in a research report on Monday, July 11th. Finally, Stifel Nicolaus dropped their price target on Becton, Dickinson and from $290.00 to $280.00 in a research report on Monday, July 18th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Becton, Dickinson and currently has a consensus rating of "Hold" and a consensus target price of $271.71.

Becton, Dickinson and Stock Up 1.7 %

Becton, Dickinson and stock traded up $4.29 during mid-day trading on Friday, hitting $263.69. The company had a trading volume of 830,905 shares, compared to its average volume of 889,830. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.58. The stock's 50 day moving average price is $245.43 and its two-hundred day moving average price is $256.10. Becton, Dickinson and has a 12 month low of $231.46 and a 12 month high of $280.62. The company has a market capitalization of $75.20 billion, a PE ratio of 45.46, a price-to-earnings-growth ratio of 3.40 and a beta of 0.59.

Becton, Dickinson and (NYSE:BDX - Get Rating) last released its earnings results on Thursday, August 4th. The medical instruments supplier reported $2.66 EPS for the quarter, topping the consensus estimate of $2.50 by $0.16. Becton, Dickinson and had a return on equity of 14.55% and a net margin of 8.88%. The business had revenue of $4.64 billion for the quarter, compared to the consensus estimate of $4.47 billion. During the same period in the previous year, the company posted $2.74 earnings per share. The company's revenue for the quarter was down 5.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Becton, Dickinson and will post 11.31 earnings per share for the current fiscal year.

Becton, Dickinson and Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 30th. Stockholders of record on Friday, September 9th will be issued a dividend of $0.87 per share. This represents a $3.48 dividend on an annualized basis and a dividend yield of 1.32%. The ex-dividend date is Thursday, September 8th. Becton, Dickinson and's payout ratio is currently 60.00%.

Insider Activity

In related news, VP Thomas J. Spoerel sold 443 shares of the company's stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $260.00, for a total transaction of $115,180.00. Following the completion of the sale, the vice president now owns 1,058 shares in the company, valued at $275,080. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, EVP Samrat S. Khichi sold 9,185 shares of the stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $260.44, for a total transaction of $2,392,141.40. Following the completion of the sale, the executive vice president now owns 5,928 shares in the company, valued at $1,543,888.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Thomas J. Spoerel sold 443 shares of the stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $260.00, for a total value of $115,180.00. Following the sale, the vice president now owns 1,058 shares of the company's stock, valued at approximately $275,080. The disclosure for this sale can be found here. Corporate insiders own 0.50% of the company's stock.

Receive BDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Becton, Dickinson and and its competitors with MarketBeat's FREE daily newsletter.

BDX Stock News Headlines

BD REPORTS THIRD QUARTER FISCAL 2022 FINANCIAL RESULTS
Denver pharmacy management company sells for $93M
Becton, Dickinson: Acquisitions Underwhelming
See More Headlines
Receive BDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Becton, Dickinson and and its competitors with MarketBeat's FREE daily newsletter.

BDX Company Calendar

Ex-Dividend for 6/30 Dividend
6/08/2022
Dividend Payable
6/30/2022
Last Earnings
8/04/2022
Today
8/14/2022
Ex-Dividend for 9/30 Dividend
9/08/2022
Dividend Payable
9/30/2022
Fiscal Year End
9/30/2022
Next Earnings (Estimated)
11/02/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
07588710
Employees
70,000
Year Founded
1897

Price Target and Rating

Average Stock Price Forecast
$271.71
High Stock Price Forecast
$310.00
Low Stock Price Forecast
$235.00
Forecasted Upside/Downside
+3.0%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$2.09 billion
Pretax Margin
10.47%

Debt

Sales & Book Value

Annual Sales
$20.25 billion
Cash Flow
$21.53 per share
Book Value
$89.38 per share

Miscellaneous

Free Float
283,769,000
Market Cap
$75.20 billion
Optionable
Optionable
Beta
0.59

Social Links















BDX Stock - Frequently Asked Questions

Should I buy or sell Becton, Dickinson and stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Becton, Dickinson and in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BDX, but not buy additional shares or sell existing shares.
View BDX analyst ratings
or view top-rated stocks.

What is Becton, Dickinson and's stock price forecast for 2022?

6 brokers have issued 1-year price targets for Becton, Dickinson and's stock. Their BDX share price forecasts range from $235.00 to $310.00. On average, they expect the company's stock price to reach $271.71 in the next twelve months. This suggests a possible upside of 3.0% from the stock's current price.
View analysts price targets for BDX
or view top-rated stocks among Wall Street analysts.

How have BDX shares performed in 2022?

Becton, Dickinson and's stock was trading at $251.48 on January 1st, 2022. Since then, BDX shares have increased by 4.9% and is now trading at $263.69.
View the best growth stocks for 2022 here
.

Are investors shorting Becton, Dickinson and?

Becton, Dickinson and saw a decrease in short interest in the month of July. As of July 31st, there was short interest totaling 2,810,000 shares, a decrease of 19.7% from the July 15th total of 3,500,000 shares. Based on an average trading volume of 1,050,000 shares, the short-interest ratio is presently 2.7 days. Currently, 1.0% of the shares of the stock are sold short.
View Becton, Dickinson and's Short Interest
.

When is Becton, Dickinson and's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our BDX earnings forecast
.

How were Becton, Dickinson and's earnings last quarter?

Becton, Dickinson and Company (NYSE:BDX) issued its quarterly earnings results on Thursday, August, 4th. The medical instruments supplier reported $2.66 earnings per share for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The medical instruments supplier had revenue of $4.64 billion for the quarter, compared to the consensus estimate of $4.47 billion. Becton, Dickinson and had a net margin of 8.88% and a trailing twelve-month return on equity of 14.55%. Becton, Dickinson and's quarterly revenue was down 5.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.74 earnings per share.
Read the conference call transcript
.

How often does Becton, Dickinson and pay dividends? What is the dividend yield for Becton, Dickinson and?

Becton, Dickinson and announced a quarterly dividend on Tuesday, July 26th. Investors of record on Friday, September 9th will be given a dividend of $0.87 per share on Friday, September 30th. This represents a $3.48 annualized dividend and a dividend yield of 1.32%. The ex-dividend date of this dividend is Thursday, September 8th.
Read our dividend analysis for BDX
.

Is Becton, Dickinson and a good dividend stock?

Becton, Dickinson and (NYSE:BDX) pays an annual dividend of $3.48 per share and currently has a dividend yield of 1.34%. The company has been increasing its dividend for 50 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 60.00%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, BDX will have a dividend payout ratio of 28.59% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for BDX.

How will Becton, Dickinson and's stock buyback program work?

Becton, Dickinson and declared that its Board of Directors has initiated a stock repurchase plan on Thursday, November 4th 2021, which allows the company to repurchase 10,000,000 outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company's board of directors believes its stock is undervalued.

What guidance has Becton, Dickinson and issued on next quarter's earnings?

Becton, Dickinson and updated its FY 2022 earnings guidance on Thursday, August, 11th. The company provided earnings per share guidance of $11.28-$11.35 for the period, compared to the consensus EPS estimate of $11.24. The company issued revenue guidance of $18.75 billion-$18.83 billion, compared to the consensus revenue estimate of $18.63 billion.

What is Tom Polen's approval rating as Becton, Dickinson and's CEO?

136 employees have rated Becton, Dickinson and Chief Executive Officer Tom Polen on Glassdoor.com. Tom Polen has an approval rating of 91% among the company's employees. This puts Tom Polen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Becton, Dickinson and own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Becton, Dickinson and investors own include Johnson & Johnson (JNJ), AbbVie (ABBV), AT&T (T), NVIDIA (NVDA), Walt Disney (DIS), Abbott Laboratories (ABT), Intel (INTC), Verizon Communications (VZ), Cisco Systems (CSCO) and CVS Health (CVS).

What is Becton, Dickinson and's stock symbol?

Becton, Dickinson and trades on the New York Stock Exchange (NYSE) under the ticker symbol "BDX."

Who are Becton, Dickinson and's major shareholders?

Becton, Dickinson and's stock is owned by a number of retail and institutional investors. Top institutional investors include Parnassus Investments LLC (1.91%), Massachusetts Financial Services Co. MA (1.83%), JPMorgan Chase & Co. (1.41%), Wells Fargo & Company MN (1.31%), Fiera Capital Corp (1.05%) and Northern Trust Corp (1.05%). Insiders that own company stock include Alexandre Conroy, Betty D Larson, Charles R Bodner, Claire Fraser, David Hickey, James C Lim, Patrick Kaltenbach, Rebecca W Rimel, Rebecca W Rimel, Ribo Alberto Mas, Roland Goette, Samrat S Khichi, Simon D Campion, Thomas J Spoerel, Thomas J Spoerel and Vincent A Forlenza.
View institutional ownership trends
.

How do I buy shares of Becton, Dickinson and?

Shares of BDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Becton, Dickinson and's stock price today?

One share of BDX stock can currently be purchased for approximately $263.69.

How much money does Becton, Dickinson and make?

Becton, Dickinson and (NYSE:BDX) has a market capitalization of $75.20 billion and generates $20.25 billion in revenue each year. The medical instruments supplier earns $2.09 billion in net income (profit) each year or $5.80 on an earnings per share basis.

How many employees does Becton, Dickinson and have?

The company employs 70,000 workers across the globe.

Does Becton, Dickinson and have any subsidiaries?

The following companies are subsidiares of Becton, Dickinson and: Accuri Cytometers, Accuri Cytometers Inc., Alverix Inc, Alverix Inc., Atto Bioscience Inc, BD Holding S. de R.L. de C.V., BD Infection Prevention BV, BD Kiestra BV, BD Kiestra Total Lab Automation, BD Rapid Diagnostic (Suzhou) Co. Ltd., BD San Luis Potosi S.A. de C.V., BD Switzerland Sarl, BD Ventures LLC, BD West Africa Limited, BDX INO LLC, Bard (Thailand) Limited, Bard ASDI Inc., Bard Access Systems Inc., Bard Acquisition Sub Inc., Bard Australia Pty. Limited, Bard Benelux N.V., Bard Brachytherapy Inc., Bard Brasil Indústria e Comércio de Produtos Para a Saúde Ltda., Bard Canada Inc., Bard Chile S.p.A., Bard Czech Republic s.r.o., Bard Devices Inc., Bard Dublin ITC Limited, Bard EMEA Finance Center Sp.z o.o., Bard European Distribution Center N.V., Bard Finance B.V. & Co. KG., Bard Financial Services Ltd., Bard Finland OY, Bard France S.A.S., Bard Global Holdings I LLC, Bard Global Holdings II LLC, Bard Global Holdings III LLC, Bard Healthcare Inc., Bard Healthcare Science (Shanghai) Limited, Bard Hellas S.A., Bard Holding SAS, Bard Holdings Limited, Bard Holdings Netherlands B.V., Bard Hong Kong Limited, Bard IP Holdings Inc., Bard India Healthcare Pvt. Ltd., Bard International Holdings B.V., Bard International Inc., Bard Istanbul Healthcare Limited Company, Bard Korea Ltd., Bard Limited, Bard MRL Acquisition Corp., Bard Malaysia Healthcare Sdn. Bhd., Bard Medica SA, Bard Medical Devices (Beijing) Co. Ltd., Bard Medical R&D (Shanghai) Co. Ltd., Bard Medical SA (Proprietary) Limited, Bard Mexico Realty S. de R.L. de C.V., Bard Norden AB, Bard Norway AS, Bard Pacific Health Care Company Ltd., Bard Peripheral Vascular Inc., Bard Poland Sp. z.o.o., Bard Productos Plasticos e Medicos Ltda., Bard Reynosa S.A. de C.V., Bard S.r.l., Bard Sdn. Bhd., Bard Shannon Limited, Bard Singapore Private Limited, Bard Sourcing Office Singapore Pte. Ltd., Bard Sweden AB, Bard UK Newco Limited, Bard de Espana S.A., Becton Dickinson (Gibraltar) Holdings Ltd., Becton Dickinson (Gibraltar) Limited, Becton Dickinson (Gibraltar) Management Limited, Becton Dickinson (Mauritius) Limited, Becton Dickinson (Pty) Ltd., Becton Dickinson (Thailand) Limited, Becton Dickinson A.G., Becton Dickinson A/S, Becton Dickinson Argentina S.R.L., Becton Dickinson Asia Holdings Ltd., Becton Dickinson Asia Limited, Becton Dickinson Austria GmbH, Becton Dickinson Austria Holdings GmbH, Becton Dickinson B.V., Becton Dickinson B.V. Saudi Limited Company, Becton Dickinson Benelux N.V., Becton Dickinson Biosciences Systems and Reagents Inc., Becton Dickinson Canada Inc., Becton Dickinson Caribe Ltd., Becton Dickinson Croatia d.o.o., Becton Dickinson Czechia s.r.o., Becton Dickinson Dispensing Belgium BVBA, Becton Dickinson Dispensing Denmark A/S, Becton Dickinson Dispensing France SAS, Becton Dickinson Dispensing Ireland Limited, Becton Dickinson Dispensing Norway, Becton Dickinson Dispensing Spain S.L.U., Becton Dickinson Dispensing UK Ltd., Becton Dickinson Distribution Center N.V., Becton Dickinson East Africa Ltd., Becton Dickinson Euro Finance Sarl, Becton Dickinson Europe Holdings S.A.S., Becton Dickinson France S.A.S., Becton Dickinson GSA Beteilgungs GmbH, Becton Dickinson Global Holdings I Inc., Becton Dickinson Global Holdings II LLC, Becton Dickinson Global Holdings IV LLC, Becton Dickinson Global Holdings V LLC, Becton Dickinson Global Holdings VII LLC, Becton Dickinson Global Holdings VIII LLC, Becton Dickinson Global Services Centre Sdn. Bhd, Becton Dickinson GmbH, Becton Dickinson Guatemala S.A., Becton Dickinson Hellas S.A., Becton Dickinson Holdings Limited, Becton Dickinson Holdings Ltd., Becton Dickinson Holdings Pte Ltd., Becton Dickinson Hungary Kft., Becton Dickinson India Private Limited, Becton Dickinson Industrias Cirurgicas Ltda., Becton Dickinson Infusion Therapy AB, Becton Dickinson Infusion Therapy Holdings UK Limited, Becton Dickinson Infusion Therapy Systems Inc., Becton Dickinson Infusion Therapy Systems Inc. S.A. de C.V., Becton Dickinson Infusion Therapy UK, Becton Dickinson Insulin Syringe Ltd., Becton Dickinson International Holdings II Pte Ltd., Becton Dickinson International Holdings III Pte Ltd., Becton Dickinson International Holdings Pte Ltd., Becton Dickinson Israel Ltd., Becton Dickinson Italia S.p.A., Becton Dickinson Ithalat Ihracat Limited Sirketi, Becton Dickinson Korea Holding Inc., Becton Dickinson Korea Ltd., Becton Dickinson Ltd., Becton Dickinson Luxembourg Finance S.a.r.L., Becton Dickinson Luxembourg Global Holdings Sarl, Becton Dickinson Luxembourg Holdings II S.a.r.L, Becton Dickinson Luxembourg Holdings III S.a.r.L, Becton Dickinson Luxembourg Holdings V S.a.r.L., Becton Dickinson Malaysia Inc., Becton Dickinson Management GmbH & Co. KG, Becton Dickinson Matrex Holdings Inc., Becton Dickinson Medical (S) Pte Ltd., Becton Dickinson Medical Devices (Shanghai) Co. Ltd., Becton Dickinson Medical Devices (Suzhou) Co. Ltd., Becton Dickinson Medical Products Pte. Ltd., Becton Dickinson Medical Technology (Jiangsu) Co. Ltd., Becton Dickinson Netherlands Global Holdings II C.V., Becton Dickinson Netherlands Holdings B.V., Becton Dickinson Netherlands Holdings II B.V., Becton Dickinson Norway AS, Becton Dickinson O.Y., Becton Dickinson Overseas Services Ltd., Becton Dickinson Pakistan (Pvt) Ltd., Becton Dickinson Penel Limited, Becton Dickinson Philippines Inc., Becton Dickinson Polska Sp.z.o.o., Becton Dickinson Portugal Unipessoal Lda., Becton Dickinson Pty. Ltd., Becton Dickinson Research Centre Ireland Limited, Becton Dickinson Rowa Germany GmbH, Becton Dickinson Rowa Italy Srl, Becton Dickinson S.A., Becton Dickinson Sample Collection GmbH, Becton Dickinson Scot Financing L.L.P., Becton Dickinson Scot Financing L.P., Becton Dickinson Sdn. Bhd., Becton Dickinson Slovakia s.r.o., Becton Dickinson Sweden AB, Becton Dickinson Sweden Holdings AB, Becton Dickinson Switzerland Global Holdings SarL, Becton Dickinson Technology Campus India, Becton Dickinson U.K. Limited, Becton Dickinson UK Financing I Limited, Becton Dickinson UK Financing II Limited, Becton Dickinson Venezuela C.A., Becton Dickinson Venture LLC, Becton Dickinson Verwaltungs GmbH, Becton Dickinson Vostok LLC, Becton Dickinson Worldwide Investments Sa.r.L., Becton Dickinson Zambia Limited, Becton Dickinson and Company Ltd., Becton Dickinson de Colombia Ltda., Becton Dickinson de Mexico S.A. de C.V., Becton Dickinson del Uruguay S.A., Bee IT Solutions, Benex Ltd., Biometric Imaging, Bridger Biomed Inc., C. R. Bard (Portugal) - Produtos e Artigos Medicos e Farmaceuticos, C. R. Bard Do Brasil Productos Medicos Ltda., C. R. Bard GmbH, C. R. Bard Inc., C. R. Bard Netherlands Sales B.V., C.R. Bard Inc, CME America LLC, CME Ltd., CME Medical (UK) Limited, CME UK (Holdings) Limited, CRISI Medical Systems, CRISI Medical Systems Inc., Caesarea Medical Electronics, Cardal II LLC, Care Fusion Development Private Limited, CareFusion (Barbados) SrL, CareFusion (Shanghai) Commercial and Trading Co. Limited, CareFusion 213 LLC, CareFusion 2200 Inc., CareFusion 2201 Inc., CareFusion 302 LLC, CareFusion 303 Inc., CareFusion Asia (HK) Limited, CareFusion Corporation, CareFusion Corporation., CareFusion D.R. 203 Ltd., CareFusion France 309 S.A.S., CareFusion Israel 330 Ltd., CareFusion Italy 312 S.p.A., CareFusion Manufacturing LLC, CareFusion Mexico 215 S.A. de C.V., CareFusion Netherlands 328 B.V., CareFusion Netherlands 503 B.V., CareFusion Netherlands 504 B.V., CareFusion Netherlands Financing 283 C.V., CareFusion Resources LLC, CareFusion S.A. 319 (Proprietary) Limited, CareFusion Solutions LLC, CareFusion U.K. 244 Limited, CareFusion U.K. 305 Limited, CareFusion U.K. 306 Limited, Carmel Pharma AB, Carmel Pharma Inc, Cato Software Solutions, Cell Analysis Systems Inc, Cellular Research, Cellular Research Inc., Clearstream Technologies Group Limited, Clearstream Technologies Limited, Clontech Laboratories Inc, Corporativo BD de Mexico S. de R.L. de C.V., Critical Device Corporation, Cubex, Cytognos, Cytopeia Inc, DLD (Bermuda) Ltd., DVL Acquisition Sub Inc., Davol Inc., Davol International Limited, Davol Surgical Innovations S.A. de C.V., Difco Laboratories Incorporated, Distribuidora BD Mexico S.A. de C.V., Dutch American Manufacturers (D.A.M.) B.V., Dymax Corporation, Embo Medical Limited, Enturia de Mexico S. de R.L. de C.V., Enturican Inc., FJ International Inc., FlowCardia Inc., FlowCardia LLC, FlowJo LLC, Franklin Lakes Enterprises L.L.C., GSL Solutions, Gamer Lasertechnik GmbH, GenCell Biosystems, GenCell Biosystems Ltd., GeneOhm Sciences Canada ULC, GeneOhm Sciences Inc, Gentest Corporation, Gesco International Inc., Gesco International LLC, Glentech Inc, HandyLab Inc, HandyLab Inc., IBD Holdings LLC, Iontophoretics Corporation, JoHome LLC, Kabushiki Kaisha Medicon (Medicon Inc.), Liberator Health and Education Services Inc., Liberator Health and Wellness Inc., Liberator Medical Holdings Inc., Liberator Medical Supply Inc., Limited Liability Company Bard Rus, Loma Vista Medical Inc., Loma Vista Medical LLC, Luther Medical Products Inc, Lutonix Inc., Med-Design Corporation, Med-Design Investment Holdings Inc., Med-Safe Systems Inc, Med-Safe Systems Inc., MedChem Products Inc., Medafor Inc., Medegen LLC, Medinservice.com Inc., Medivance Inc., NAT Diagnostics Inc., NAT Diagnostics Inc., NOW Medical Distribution Inc., NOW Medical Distribution LLC, Navarre Biomedical LLC, Navarre Biomedical Ltd., Neomend Inc., Nippon Becton Dickinson Company Ltd., Omega Biosystems Incorporated, P.R.C. (Isialys) Societe a responsabilitie limitee, PT Becton Dickinson Indonesia, PharMingen, PharMingen., Plasso Technology Ltd, PreAnalytiX GmbH, Pristine Access Technologies Inc., ProSeed Inc., Procesos para Esterilizacion S.A. de C.V., Productos Bard de Mexico S.A. de C.V., Productos Para el Cuidado de la Salud S.A. de C.V., Puls Medical Devices AS LC, PureWick Corporation, Roberts Laboratories Inc., Rochester Medical Corporation, Rochester Medical Ltd., Saf-T-Med Inc, Safety Syringes Inc., Scanwell Health Inc., Sendal S.L.U., SenoRx Inc., SenoRx LLC, Shield Healthcare Centers Inc., Sirigen Group Limited, Sirigen II Limited, Sirigen Inc., Sistemas Médicos ALARIS S.A. de C.V., Specialized Cooperative Corporation, Specialized Health Products Inc., Specialized Health Products International Inc., Specialized Health Products International LLC, Staged Diabetes Management LLC, Straub Medical AG, Straub Medical AG, Surgical Site Solutions Inc., TVA Medical Inc, TVA Medical Inc., Tepha Inc, Tepha Inc., Tissuemed Ltd., Tri-County Medical & Ostomy Supplies Inc., TriPath Imaging Inc., Tru-Fit Marketing Corporation, Vas-Cath Incorporated, Vascular Pathways Inc., Velano Vascular, Velano Vascular Inc., Venclose Inc., Venetec International Inc., Venetec International LLC, Visitec, Y-Med Inc., Y-Med LLC, and ZebraSci Inc..
Read More

When was Becton, Dickinson and founded?

Becton, Dickinson and was founded in 1897.

How can I contact Becton, Dickinson and?

Becton, Dickinson and's mailing address is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. The official website for the company is www.bd.com. The medical instruments supplier can be reached via phone at (201) 847-6800 or via fax at 201-847-6475.

This page (NYSE:BDX) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.